AAVB 081
Alternative Names: AAVB-081Latest Information Update: 16 Dec 2024
Price :
$50 *
At a glance
- Originator AAVantgarde Bio
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference; Myosin VIIa replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Usher syndrome type 1B